CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ -- Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome ...

Novel use of Causal AI revives long-stalled development pathways across complex generics and next-generation medicines for chronic disease Allos bends the cost-risk curve of drug development and ...

Carmel-based venture capital firm Allos Ventures plans to launch its third and biggest fund to date while also hiring its third managing director. The 8-year-old firm, which focuses on investing in ...

TEL AVIV (MarketWatch) -- Allos Therapeutics Inc., the Westminster, Colo., biopharma focused on cancer drugs, agreed to be acquired by Spectrum Pharmaceuticals Inc. for $1.82 cash plus a contigent ...

Allos Ventures, an Indianapolis-based venture capital firm, will continue its buy in on the Midwest with the $52 million close of its latest fund, Allos III. That investment, leadership said, will ...

INDIANAPOLIS (Inside INdiana Business) — Indianapolis-based Allos Ventures has announced the first closing of its latest fund, Allos IV. The venture capital firm says the fund will continue its focus ...

R$1.3 billion in divestments. ALLOS announced total and partial divestments from six of its malls, totaling R$1.3 billion, with an average cap rate of 8.1%. The transactions reinforce the Company's ...

BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...